الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 164 |  |  |
| | | from | 164 | | |
Abstract
AML is a diverse disease that occurs when hematopoietic stem cells undergo malignant transformation. Despite numerous continuing clinical drug trials, the intense 3 + 7 induction regimen consisting of anthracyclines and cytarabine has consistently been considered the most effective treatment for AML for more than four decades.
Attaining hematological CR with chemotherapy is a crucial prognostic indicator for the survival of patients. Regrettably, a significant proportion of AML patients, specifically 40% of those under 60 years old and 60% of those over 60 years old, fail to attain complete remission (CR) following the initial round of 3 + 7 induction therapy.